SBIR/STTR Research Award
Biointegrated Synthetic Grafts for Reconstruction of Vascular Tissue
Award amount
$999,690Program and phase
SBIR · Phase IIAward year
2016Award details
- Awarding agency
- Department of Defense
- Branch
- Defense Health Agency
- Recipient company
- HEALIONICS CORPORATION
- Proposal award date
- 2016-02-22
- Contract end date
- 2018-07-21
- UEI
- KS25PLAKN3X3
- Solicitation number
- 2014.2
- Topic code
- DHP14-009
Research abstract
Use ofexisting smaller prosthetic grafts for vascular repair and reconstruction after severetrauma to the extremities is greatly limited by issues with stenosis and infection.We propose treating the exterior of ePTFE vascular grafts with STAR biomaterial, a well-developed microporous synthetic tissue scaffold already in human use.STAR prevents the usual formation of a constrictive fibrotic perigraft tissue capsule.Mechanical constriction effects areeliminated, permitting greater freedom for natural pulsatile and vibratory motion of the graft wall.This suppresses progression of neointimal hyperplasia by alleviating compliance mismatch and providing more favorable stress conditions at the ePTFE-neointima interface.The STAR biointerface also addresses the infection risk of ePTFE grafts; STAR biomaterial harnesses the bodys natural antimicrobial defenses by concentrating immune cells to resist infections.These biological responses are regulated by the tightly controlled and optimized porous geometry and do not require use of added biologics.Promising preliminary results suggest that this approach can lead to a major improvementin clinical performance and reliability.Phase II technical objectives aredemonstrating advantages of superior patency and infection control in an ovine arterial bypass model with controlled bacterial challenge, and performing neededbench testingtowards qualifyingthe novel graft design for human use.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Commercial and Regulatory Development of an Enhanced Performance Hemodialysis Access Graft
- Product and Regulatory Development of a Needle-Free Hemodialysis Access Port
- Infection Resistant Hemodialysis Access Graft
- Clinical Study of an Extended Patency Dialysis Access Graft
- Biointegrating Dialysis Access Graft with Self Stabilizing Flow